Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, July 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 1,262 followers.

New NNT→Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age https://t.co/Qjt1Re2AQl

30 Jul 2022

Reply Repost Favourite

Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis https://t.co/kbz8u3O9BZ

09 Jul 2022

Reply Repost Favourite

Dove Medical Press

Article Metrics

Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals Age <65 with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction: A Cost–Benefit Analysis

Mentioned by

Citations

Readers on